- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Melanoma | Clinical
FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin
July 21, 2021
The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for the treatment of stage 2b to 4 melanoma.
More Research on Potency, Efficacy of TILs Is Needed in Melanoma
July 07, 2021
According to Inge Marie Svane, MD, PhD, the truth about what drives tumor-infiltrating lymphocyte efficacy is not yet known, and more research is needed.
Neoadjuvant Is Superior to Adjuvant Immunotherapy in Stage III Melanoma
June 22, 2021
Research has suggested that neoadjuvant immunotherapy combinations are superior to adjuvant immunotherapy for patients with stage III melanoma.
Adjuvant Targeted Therapy Proves Beneficial in Resected Stage III BRAF-Mutant Melanoma
June 21, 2021
Targeted therapy use in melanoma has been extended beyond just metastatic disease to now include adjuvant therapy for patients with resected stage III melanoma.
APG-115 Plus Pembrolizumab Safe With Preliminary Efficacy in Unresectable or Metastatic Melanoma or Advanced Solid Tumors
June 08, 2021
The combination of alrizomadlin and pembrolizumab was well tolerated in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immuno-oncologic drugs treated in a phase 2 study.
Nivolumab Alone, Or With Ipilimumab Maintains Improved Outcomes in Advanced Melanoma
June 06, 2021
Looking at 6.5 years of follow-up data from the phase 3 CheckMate-067 trial shows maintained outcomes in patients with advanced melanoma on nivolumab alone, or with ipilimumab.
Maximized Benefit of Lifileucel in Melanoma Potentially Seen Following Anti–PD-1 Progression
June 06, 2021
Further follow up of lifileucel in patients with melanoma showed potentially follow progression on anti—PD-1 therapy.
Lenvatinib and Pembrolizumab Show Continuing Efficacy in Certain Patients With Advanced Melanoma
June 06, 2021
In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma, efficacy results continue to show a durable response.
Positive Responses, PFS for Pembrolizumab-Naïve Patients Continue, But Lower Efficacy Reported in Rechallenged Population
June 06, 2021
Treatment-naïve patients with melanoma who crossed over to receive pembrolizumab had an ORR of 38.8% and a 3-year PFS of 32% according to updated data from the phase 3 EORTX 1325/KEYNOTE-054 trial.
PFS Doubles for Advanced Melanoma Patients Treated with Relatlimab Plus Nivolumab
May 19, 2021
PFS Doubles for Advanced Melanoma Patients Treated with Relatlimab Plus Nivolumab.